公开(公告)号：WO2020005888A1

公开(公告)日：2020-01-02

申请号：PCT/US2019/038908

申请日：2019-06-25

申请人： CYTOKINETICS, INC.

发明人： MORGAN, Bradley P. ,  VANDERWAL, Mark ,  CHUANG, Chihyuan

IPC分类号： C07D413/12 ,  C07D271/06 ,  A61P9/00 ,  A61K31/4245

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , Y 1 , Y 2 , L 1 , and G 1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2020047447A1

公开(公告)日：2020-03-05

申请号：PCT/US2019/049118

申请日：2019-08-30

申请人： CYTOKINETICS, INC.

发明人： CHUANG, Chihyuan ,  MORGAN, Bradley P. ,  VANDERWAL, Mark ,  ASHCRAFT, Luke W. ,  LAU, Kevin

IPC分类号： A61P9/00 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/10 ,  C07D487/10 ,  C07D491/107 ,  A61K31/496 ,  A61K31/499

摘要： Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2A , R 2B , R 3 , R 4 , and R 5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2019144041A1

公开(公告)日：2019-07-25

申请号：PCT/US2019/014344

申请日：2019-01-18

申请人： CYTOKINETICS, INC.

发明人： CHUANG, Chihyuan ,  MORGAN, Bradley P. ,  VANDERWAL, Mark ,  WANG, Wenyue ,  ASHCRAFT, Luke W.

IPC分类号： C07D403/12 ,  C07D413/14 ,  C07D231/14 ,  C07D401/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D271/06 ,  A61P9/04 ,  A61K31/4196

摘要： Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R 1 , R 2 , R 3 , G 1, G 2 , and G 3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.